Suir Engineering delivered a two-phase development at the Dundalk site, comprising a biologics Phase 1 manufacturing facility and a Phase 2 vaccines facility, supporting the production of advanced biologic medicines and vaccines.
The development consists of seven buildings across both phases. Key elements include a three-storey manufacturing facility with a floor area of 21,020m², and an 11,051m² laboratory and administration building incorporating a mechanical penthouse across four floors.
The project also includes a two-storey combined utilities building (2,230m²), featuring three 25m-high boiler stacks, along with a single-storey electrical building, a single-storey security building, and a wastewater treatment plant designed to service all site facilities.
Suir Engineering’s full scope of work is detailed below.